# Wall Street Zen

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/wall-street-zen-company
Canonical HTML page: https://getbiobrief.com/entity/wall-street-zen-company

## Timeline

- **2026-Q3 (estimated)**: Clinical Catalyst — Anticipated data readouts for sevasemten in Becker Muscular Dystrophy trials.
- **2026-03-17**: Wall Street Zen Downgrade — SABS and SSSS both receive Sell ratings from Wall Street Zen.
- **2026-02-27**: 52-Week High — EWTX stock reaches a new yearly peak amid clinical pipeline optimism.
- **2026-02-17**: Analyst Upgrade — Wall Street Zen raises Edgewise Therapeutics to a 'Hold' rating.
- **2025-Q4**: SAB-142 Clinical Progress — SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
- **2025**: Strategic Pivot — Company shifts focus from infectious diseases to immunology and chronic conditions.

## Recent coverage (5 stories)

### Biotech Sell-Off: Novavax Downgraded to Sell Despite Revenue Beat
2026-08-04 12:11:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Full story: https://getbiobrief.com/story/novavax-sell-downgrade-biotech-pharma

### SAB Biotherapeutics Downgraded to Sell Amid Shifting Biotech Sentiment
2026-03-17 06:51:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.
Full story: https://getbiobrief.com/story/sab-biotherapeutics-downgraded-sell-wall-street-zen

### Wall Street Zen Upgrades Codexis and Enovis on Strong 2026 Growth Outlooks
2026-03-16 06:31:28 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Full story: https://getbiobrief.com/story/codexis-enovis-stock-upgrades-wall-street-zen

### Organogenesis Upgraded to Buy as Regenerative Medicine Gains Momentum
2026-03-08 08:30:35 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Wall Street Zen has upgraded Organogenesis (NASDAQ: ORGO) to a 'Buy' rating, signaling increased confidence in the regenerative medicine specialist's market position. This move comes amid a broader wave of optimistic re-ratings for mid-cap growth stocks across multiple sectors, including oilfield services and software.
Full story: https://getbiobrief.com/story/organogenesis-orgo-upgraded-buy-rating-wall-street-zen

### Edgewise Therapeutics Hits 52-Week High as Muscle Disease Pipeline Gains Momentum
2026-02-27 17:04:57 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Edgewise Therapeutics (NASDAQ: EWTX) has reached a new 52-week high, reflecting growing investor confidence in its clinical-stage pipeline for rare muscle and cardiac diseases. The surge follows recent analyst upgrades and positive sentiment surrounding its lead candidates, sevasemten and EDG-7500.
Full story: https://getbiobrief.com/story/edgewise-therapeutics-ewtx-52-week-high-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.